Last reviewed · How we verify
NCT05182151
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
trial testing Istradefylline 40 mg in Apathy in 8 participants. Terminated before completion.
1 December 2023
Quick facts
| Lead sponsor | Medical University of South Carolina |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 29 July 2022 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Istradefylline 40 mg — full drug profile →
Conditions studied
- Apathy — all drugs for Apathy →
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Medical University of South Carolina
Who can join
Adults 18 to 99, any sex, with Apathy or Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Apathy is defined as a lack of feeling, emotion, interest, or concern. Apathy also involves reduction or loss of motivation and goal-directed behavior. Clinically significant apathy, where meaningful activities are given up and quality of life is diminished, is common in people with Parkinson's disease (PD). Many individuals with Parkinson's disease experiencing fluctuations in the severity of their movement problems and medication "off" time. "Off" time refers to periods of the day between doses of PD medication when your motor symptoms (e.g., tremor, stiffness, slowness, walking problems, etc.) are worse and interfere with your ability to complete tasks of daily living. The investigational drug, Istradefylline, is an FDA-approved medication to treat motor fluctuations and "off" time in PD. The purpose of this study is to investigate whether people with Parkinson's disease (PD) who are treated with istradefylline (ISD) show improvements in motivation and apathy over a 12-week period. Specifically, we wish to see whether people with PD who are treated with ISD engage in more physical and recreational activities, such as hobbies and other interests.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Fountain of youth-Targeting autophagy in aging.
Danics L, Abbas AA, Kis B, Pircs K. · · 2023 · cited 2× · PMID 37065462 · DOI 10.3389/fnagi.2023.1125739
Verify or expand the search:
- PubMed search for NCT05182151
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Apathy
Currently open trials in the same condition.
- NCT05877885 — Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics · NA · recruiting
- NCT06919094 — A Virtual Life Story Club Intervention to Improve Loneliness and Apathy in Community-Dwelling Older Adults · NA · recruiting
- NCT07113067 — Accelerated rTMS vs. Sham for Stroke Apathy · Phase 1, PHASE2 · recruiting
- NCT07118956 — Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease · NA · recruiting
- NCT05232877 — Effects of t-DCS and Cognitive Training on Apathy in Elderly With Minor Neurocognitive Impairment · NA · active not recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
- NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
- NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
- NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
- NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05182151 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
- Last refreshed: 2 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05182151.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing